Zymeworks Inc. (NASDAQ:ZYME) Given Average Rating of “Buy” by Brokerages

Zymeworks Inc. (NASDAQ:ZYME) has received a consensus recommendation of “Buy” from the five ratings firms that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a strong buy rating on the company.

ZYME has been the topic of several research reports. HC Wainwright raised Zymeworks from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 14th. Wells Fargo & Company raised Zymeworks to a “hold” rating in a report on Friday, October 24th. Wall Street Zen cut Zymeworks from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Zacks Research raised shares of Zymeworks from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 28th. Finally, B. Riley upgraded shares of Zymeworks to a “strong-buy” rating in a research note on Thursday, October 9th.

Zymeworks Price Performance

Shares of ZYME opened at $24.02 on Monday. The company has a 50-day moving average of $18.19. The company has a market capitalization of $1.80 billion, a price-to-earnings ratio of -24.76 and a beta of 1.48. Zymeworks has a fifty-two week low of $9.03 and a fifty-two week high of $26.19.

Zymeworks (NASDAQ:ZYME) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.04. The business had revenue of $27.61 million for the quarter, compared to analyst estimates of $28.27 million. Zymeworks had a negative net margin of 59.96% and a negative return on equity of 21.59%.

About Zymeworks

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.